JUL 11, 2017 1:52 PM PDT

These Two Molecules Appear to Drive Breast Cancer Drug Resistance

Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options.

Now, scientists from the Florida campus of The Scripps Research Institute (TSRI), the University of California (UC), San Diego and the University of Illinois have found that two immune system molecules may be key to the development of drug resistance in estrogen-driven breast cancers.

The researchers believe this finding may open the door to novel therapeutic approaches and influence treatment decisions for the tens of thousands of patients who suffer from estrogen-driven breast cancers.

These molecules, which are cytokines called interleukin 1 beta (IL1β) and tumor necrosis factor alpha (TNFα), had previously been linked to the spread of drug-resistant cancer, but scientists were unsure of the exact mechanisms that led these molecules to drive drug resistance.

The new study, published online ahead of print in the journal Molecular Cell, reveals that IL1β and TNFα turn on pathways that modify the actual shape of the estrogen receptor. This phenomenon appears to drive resistance to the common anti-cancer drug tamoxifen.

“Cytokines change the shape of the estrogen receptor, and that change overrides the inhibitory effects of tamoxifen and leads to drug resistance,” said TSRI Associate Professor Kendall Nettles, who led the new study alongside senior author Christopher K. Glass and study first author Joshua D. Stender of UC San Diego. “These findings dramatically alter our understanding of the biological actions of pro-inflammatory cytokines in breast cancer cells.” 

Striking Back at Drug Resistance

Using a combination of genomic, cellular, biochemical and structural approaches, the researchers found that the way these cytokines alter the estrogen receptor are sufficient to induce growth of breast cancer cells in the absence of estrogen, precisely what happens when breast cancer is initially treated with an endocrine therapy like tamoxifen. Scientists found that in addition to reversing tamoxifen suppression of growth, cytokine activation of the estrogen receptor also enhanced the invasive properties of a specific line of human breast cancer cells known as MCF-7, the most studied human breast cancer cell in in the world.

Using x-ray crystallography, Nettles and his colleagues developed an atomic snapshot of the estrogen receptor to show how these shape changes occur and how the process might be blocked.

Nettles pointed out that both inflammation and immune cells are known causes of resistance, but if that inflammation can be blocked, resistance can be reduced or eliminated.

“These tumors can reprogram the immune cells to their advantage so that the cells become tumor supportive,” Kettles said. “We think we can produce hormone therapies that can, in essence, re-reprogram the immune system or prevent it from altering the receptor in the first place, which is an obvious strategy for blocking these adverse effects. Importantly, our atomic snapshot of the receptor showed that the same mechanism can explain how Her2Neu or other growth promoting factors, as well as certain invasion and motility signals also cause resistance to anti-hormone therapies.”

This research was supported by the National Institutes of Health (grants R01DK091183, R01DK015556, R01CA17390 and P30 DK063491), Frenchman’s Creek Women for Cancer Research and The BallenIsles Men’s Golf Association.

This article was originally published on scripps.edu

About the Author
  • The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists-including two Nobel laureates-work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
You May Also Like
FEB 04, 2020
Microbiology
FEB 04, 2020
Revealing How a Common Virus Evades the Immune System
The human metapneumovirus (HMPV) might now be well-known, but it is the second biggest cause of respiratory infections....
FEB 06, 2020
Health & Medicine
FEB 06, 2020
Scientists Found a Safe BPA Alternative
BPA—bisphenol A—is an industrial chemical used in a wide range of everyday consumer products. From food and beverage can linings and storage co...
FEB 12, 2020
Drug Discovery & Development
FEB 12, 2020
Does Traditional Chinese Medicine Work Against Coronavirus?
Over 45,000 cases of Wuhan Coronavirus have been reported globally, alongside over 1,100 deaths. Although over 4,700 people are said to have recovered from...
FEB 21, 2020
Clinical & Molecular DX
FEB 21, 2020
Diagnosing COVID-19
Diagnosing coronavirus is done through next-generation sequencing, real-time RT-PCR tests, cell culture, and electron miscopy. For patients, that translate...
FEB 25, 2020
Cardiology
FEB 25, 2020
Simple Blood Test May Prevent Deaths from Heart Attack
Cardiovascular disease is responsible for almost 18 million deaths every year, making it the top killing-disease in the world. Now, researchers at Newcastl...
FEB 26, 2020
Microbiology
FEB 26, 2020
NIAID Tests Remdesivir as a Treatment for COVID-19
A case of coronavirus has now occured in the US in someone without a known link to an infected person or travel....
Loading Comments...